Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trialDaniel S. Reich, Sibyl Wray, Bernard M.J. Uitdehaag et al.|The Lancet Neurology|2021Cited by 192